Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.

ABSTRACT: Chemotherapy-induced thrombocytopenia (CIT) is common, resulting in increased bleeding risk and chemotherapy delays, dose reduction, and treatment discontinuation, which can negatively affect oncologic outcomes. The only agent approved by the US Food and Drug Administration to manage CIT (oprelvekin) was voluntarily withdrawn from the market by the manufacturer, leaving few options for patients. Therefore, patients experiencing CIT present a significant clinical challenge in daily practice. The availability of thrombopoietin receptor agonists has led to formal clinical trials describing efficacy in CIT as well as a rather extensive body of published observational data from off-label use in this setting but no formal regulatory indications for CIT to date. The accumulated data, however, hav

SUBMITTER: Al-Samkari H 

PROVIDER: S-EPMC9821429 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature